Back to the Future—the Tragedy of Unrelieved Pain and Suffering – PAINS – Pain Action Alliance to Implement a National Strategy – PAINS Project | Jun 15, 2017 |by Richard Payne, MD, Medical Director, PAINS Project
As a young doctor I attended a conference at MD Anderson Cancer Center titled “Treating Pain in a Drug Oriented Society.”
One of the conference keynote speakers, Dr. Kathleen Foley, called for the “decriminalization” of cancer pain, noting that (even back then) the American Medical Association,
- the American Pain Society,
- the American College of Physicians and
- the World Health Organization
recognized that opioid pharmacotherapy was the mainstay of treatment for patients with cancer experiencing moderate to severe pain.
Citing surveys that she and colleagues had conducted at Memorial Sloan-Kettering Cancer Center, she noted that fear of addiction and risk of substance abuse were over riding concerns of physicians, patients and families and called for prospective studies of abuse liability and educational programs for clinicians to improve cancer pain management
Such was the world in 1989.
- innumerable clinical research trials,
- the development and FDA approval of several long-acting opioids for cancer-related pain,
- countless educational efforts (industry and non-industry funded) and
- the dissemination of numerous clinical practice guidelines
over the past 36 years, it seems that the proverbial pendulum has swung back to a gloomier time in which cancer patients are once again being denied opioid therapy as are many others who live with persistent disabling chronic pain.
Clearly the tragedy of the current opioid epidemic has negatively influenced clinician, patient and family attitudes about opioid therapy for pain management, even for those with cancer pain.
As Susan Glod described in her recent NEJM article, “The Other Victims of the Opioid Epidemic,” she is accused of “making monsters” when she advocates for more aggressive opioid analgesia for her dying patient Jerry.
Dr. Glod makes a very important point that the “opioid epidemic” has so seized the attention of us all that, “We have placed the blame for the tragic losses of so many lives in so many communities on the drugs themselves rather than on the complex interplay of factors that has led to the current crises.
This distorted thinking is the basis for challenging the credentials and integrity of many advocates for persons in chronic pain who have worked in good faith with the pharmaceutical industry on joint efforts to bring improved opioids to clinical practice, or to create and disseminate educational programs to improve pain management.
The mantra of the NLS Campaign is that “Better chronic pain treatment will improve the lives of millions of Americans, save billions of dollars, and reduce opioid misuse.”
We must advocate for the continued use of opioid analgesics when indicated in cancer pain management and hospice care, and the judicious use of opioid analgesics as part of a process of comprehensive assessment and management of chronic pain.
As Dr. Glod’s essay so poignantly reminds us, we cannot allow the tragedy of the “opioid epidemic” to induce us to accept as collateral victims those with cancer pain responsive to opioids or to silence us in this important advocacy work to speak for those with chronic pain.